Good morning :)
Place Order
Add to Watchlist

Alembic Pharmaceuticals Ltd

APLLTD

Alembic Pharmaceuticals Ltd

APLLTD
Health CarePharmaceuticals
SmallcapWith a market cap of ₹21,712 cr, stock is ranked 334
Moderate RiskStock is 2.76x as volatile as Nifty
1,049.450.33% (+3.45)
1,049.450.33% (+3.45)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹21,712 cr, stock is ranked 334
Moderate RiskStock is 2.76x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹21,712 cr, stock is ranked 334
Moderate RiskStock is 2.76x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
33.574.511.00%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
45%
Analysts have suggested that investors can buy this stock

from 11 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).

Investor Presentation

View older 

Nov 7, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.67%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.8% to 1.66%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 1.05%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue3,173.113,107.173,137.843,944.064,610.695,480.425,361.535,655.366,256.936,396.64
Raw Materialssubtract877.07928.05927.621,084.971,249.981,451.271,489.611,630.171,857.925,355.17
Power & Fuel Costsubtract58.8964.2070.3588.86102.40118.72120.84151.54173.37
Employee Costsubtract472.85558.83622.81746.69906.441,051.171,133.001,169.131,446.29
Selling & Administrative Expensessubtract507.40791.13700.51961.11913.651,104.031,354.871,474.001,543.70
Operating & Other expensessubtract243.09147.67166.42179.47253.92187.65333.31550.33274.96
Depreciation/Amortizationsubtract72.2182.97105.46115.23157.32183.48286.78275.43272.67278.48
Interest & Other Itemssubtract5.435.233.4018.4127.1616.0217.7350.1756.1958.10
Taxes & Other Itemssubtract216.12125.93128.64164.95171.00221.58104.4512.6016.0158.11
EPS38.2021.3921.8931.0043.9759.5526.5017.4031.3332.90
DPS3.504.004.005.5010.0014.0010.008.0011.0011.00
Payout ratio0.090.190.180.180.230.240.380.460.350.33

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2016

Annual report

PDF

Investor Presentation

Jan 21PDF
FY 2017

Annual report

PDF

Investor Presentation

Jul 29PDF
FY 2023

Annual report

PDF

Investor Presentation

May 5PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 4PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 7PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alembic Pharmaceuticals Ltd35.264.511.00%
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare APLLTD with any stock or ETF
Compare APLLTD with any stock or ETF
APLLTD
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding69.61%8.90%7.16%3.94%10.39%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep4.35%4.51%4.52%4.46%4.32%3.94%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Kotak Small Cap Fund - Growth - Direct Plan

Growth
1.7243%2.11%0.05%12/83 (+28)
DSP Midcap Fund - Growth - Direct Plan

Growth
1.4740%1.68%-0.01%25/62 (+3)
Axis Small Cap Fund - Growth - Direct Plan

Growth
0.7273%0.65%0.00%34/132 (+54)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

APLLTD has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.00%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.96 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 15, 2024

Final
Final | Div/Share: ₹11.00

Dividend/Share

₹11.00

Ex DateEx Date

Jul 15, 2024

Cash Dividend

Ex DateEx DateJul 28, 2023

Final
Final | Div/Share: ₹8.00

Dividend/Share

₹8.00

Ex DateEx Date

Jul 28, 2023

Cash Dividend

Ex DateEx DateAug 17, 2022

Interim
Interim | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Aug 17, 2022

Cash Dividend

Ex DateEx DateJul 19, 2021

Final
Final | Div/Share: ₹14.00

Dividend/Share

₹14.00

Ex DateEx Date

Jul 19, 2021

Cash Dividend

Ex DateEx DateMar 16, 2020

Special
Special | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Mar 16, 2020

News & Opinions
Spotlight
Alembic Pharma Panelav unit clears Brazil GMP audit

Alembic Pharmaceuticals has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit at active pharmaceutical ingredient (API)-II Facilty at Panelav for its 8 APIs. The inspection was conducted from 16 to 20 September 2024. Alembic Pharmaceuticals is in the business of the development, manufacturing, and marketing of pharmaceutical products, i.e., formulations and active pharmaceutical ingredients. The pharmaceutical company's consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024. The scrip slipped 1.34% to currently trade at Rs 1,088.95 on the BSE.Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Alembic Pharma receives USFDA's tentative approval for Olopatadine Hydrochloride Ophthalmic Solution

Alembic Pharmaceuticals announced that it has received Tentative Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pataday Once Daily Relief Ophthalmic Solution, 0.7%, of Alcon Laboratories, Inc. (Alcon) NDA - 206276. Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Alembic Pharma gets USFDA nod for Olopatadine Hydrochloride eye drops

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pataday Once Daily Relief Ophthalmic Solution, of Alcon Laboratories, Inc. Olopatadine Hydrochloride Ophthalmic Solution USP is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander. According to IQVIA, Olopatadine Hydrochloride Ophthalmic Solution USP has an estimated market size of $22 million for twelve months ending September 2024. Alembic has a cumulative total of 219 ANDA approvals (192 final approvals and 27 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of the development, manufacturing, and marketing of pharmaceutical products, i.e., formulations and active pharmaceutical ingredients. The pharmaceutical company's consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024. The scrip rose 0.06% to currently trade at Rs 1,101.05 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Alembic Pharma Gujarat facility gets 5 observations from USFDA

The GMP inspection was conducted from 14 November 2024 to 22 November 2024. The USFDA issued Form-483 with 5 observations. The company stated that it would provide a comprehensive response to the USFDA for the observations within the stipulated period. It also committed to maintaining the highest quality standards and compliance at all times. Alembic Pharmaceuticals is in the business of development, manufacturing and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 12.3% to Rs 153.41 crore in Q2 FY25 as compared to Rs 136.56 crore posted in Q2 FY24. Revenue from operations grew 3.3% year on year (YoY) to Rs 1,647.98 crore in the quarter ended 30 September 2024. The scrip rallied 3.44% to currently trade at Rs 1,077.60 on the BSE. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Alembic Pharmaceuticals receives USFDA approval for Ivabradine Tablets

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ivabradine Tablets, 5 mg and 7.5 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Corlanor Tablets, 5 mg and 7.5 mg, of Amgen Inc. (Amgen). Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US$ 145.3 million for twelve months ending September 2024 according to IQVIA. Alembic has a cumulative total of 218 ANDA approvals (192 final approvals and 26 tentative approvals) from USFDA.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Alembic Pharma gets US FDA nod for Diltiazem Hydrochloride ER capsules

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cardizem CD extended-release capsules of Bausch Health US, LLC. The approved strengths for the said drug are 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. Diltiazem Hydrochloride Extended-Release (ER) capsules are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications. It is also indicated for the management of chronic stable angina and angina due to coronary artery spasm. Diltiazem Hydrochloride extended-release capsules have an estimated market size of $105.3 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip fell 1.89% to currently trade at Rs 1019.35 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Alembic Pharmaceuticals receives USFDA approval for Diltiazem Hydrochloride ER capsules

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cardizem CD Extended-Release Capsules, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, of Bausch Health US, LLC. Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications. It is also indicated for the management of chronic stable angina and angina due to coronary artery spasm. Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of US$105.3 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from USFDA. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Alembic Pharmaceuticals consolidated net profit rises 12.34% in the September 2024 quarter

Net profit of Alembic Pharmaceuticals rose 12.34% to Rs 153.41 crore in the quarter ended September 2024 as against Rs 136.56 crore during the previous quarter ended September 2023. Sales rose 3.33% to Rs 1647.98 crore in the quarter ended September 2024 as against Rs 1594.93 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1647.981594.93 3 OPM %14.5213.03 - PBDT238.06202.20 18 PBT167.55134.64 24 NP153.41136.56 12 Powered by Capital Market - Live

1 month agoCapital Market - Live
Live Market Update
Nifty slips below 24,750 mark; Waree Energies IPO fully subscribed; VIX jumps over 7%

The headline equity benchmarks traded with limited losses in early-afternoon trade. The Nifty traded below the 24,750 mark. Metal shares decline after rising for the past trading session. At 11:25 IST, the barometer index, the S&P BSE Sensex, was down 197.25 points or 0.24% to 81,026.95. The Nifty 50 index fell 105.15 points or 0.42% to 24,748.90. In the broader market, the S&P BSE Mid-Cap index fell 0.46% and the S&P BSE Small-Cap index shed 0.99%. The market breadth was weak. On the BSE, 1,254 shares rose and 2,637 shares fell. A total of 154 shares were unchanged. Waree Energies IPO received strong interest from investors. The IPO received bids for 3,16,95,741 shares as against 2,10,79,384 shares on offer. The IPO was subscribed 1.50 times. Economy: India's net direct tax collections jumped by 182.02% over last decade to Rs 19.60 lakh crore in FY24, from 6.95 lakh crore in FY15, following strong growth in personal income tax, the latest time series data from the Income Tax Department showed. Personal income tax collections zoomed up nearly 300% to Rs 10.45 lakh crore, from 2.65 lakh crore in FY15, outpacing corporate tax collections, which rose by 112.85% to Rs 9.11 lakh crore from Rs 4.28 lakh crore in FY15. Derivative: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, advanced 7.09% to 13.96. The Nifty 31 October 2024 futures were trading at 24,760.60, at a premium of 95.70 points as compared with the spot at __ . The Nifty option chain for the 31 October 2024 expiry showed maximum Call OI of 92.8 lakh contracts at the 25,000 strike price. Maximum Put OI of 44.2lakh contracts were seen at 24,000 strike price. Buzzing Index: The Nifty Metal index fell 1.40% to 9,617.75. The index advanced 1.57% in the past trading session. Jindal Stainless Ltd (down 5.84%), APL Apollo Tubes Ltd (down 2.42%), NMDC Ltd (down 2.14%), Adani Enterprises Ltd (down 2.1%) and Hindustan Copper Ltd (down 2.04%), Steel Authority of India Ltd (down 1.77%), Hindalco Industries Ltd (down 1.55%), National Aluminium Company Ltd (down 1.49%), Vedanta Ltd (down 0.93%) and JSW Steel Ltd (down 0.9%) declined. Stock in Spotlight: Alembic Pharmaceuticals rose 0.21%. The company has announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Alembic Pharmaceuticals to discuss results

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 November 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live